Literature DB >> 13483889

Clinical implications of isoniazid blood levels in pulmonary tuberculosis.

R S MITCHELL, J C BELL.   

Abstract

Entities:  

Keywords:  TUBERCULOSIS, PULMONARY/blood in

Mesh：

Substances：

Year:  1957        PMID： 13483889     DOI： 10.1056/NEJM195711282572202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

2.  Inactivation of isoniazid by Canadian Eskimos and Indians.

Authors:  C W Jeanes; O Schaefer; L Eidus
Journal:  Can Med Assoc J       Date:  1972-02-19       Impact factor: 8.262

3.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis.

Authors:  P R GANGADHARAM; A L BHATIA; S RADHAKRISHNA; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

4.  Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.

Authors:  G Acocella; L Bonollo; M Garimoldi; M Mainardi; L T Tenconi; F B Nicolis
Journal:  Gut       Date:  1972-01       Impact factor: 23.059

Review 5.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

Review 6.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

7.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS.

Authors:  J B SELKON; W FOX; P R GANGADHARAM; K RAMACHANDRAN; C V RAMAKRISHNAN; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

8.  A CLINICAL STUDY OF ISONIAZID INACTIVATION.

Authors:  A G JESSAMINE; E J HAMILTON; L EIDUS
Journal:  Can Med Assoc J       Date:  1963-12-14       Impact factor: 8.262

9.  BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.

Authors:  J F MUSTARD; E A MURPHY; M A OGRYZLO; H A SMYTHE
Journal:  Can Med Assoc J       Date:  1963-12-14       Impact factor: 8.262

10.  The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Authors:  P R Donald; D P Parkin; H I Seifart; H S Schaaf; P D van Helden; C J Werely; F A Sirgel; A Venter; J S Maritz
Journal:  Eur J Clin Pharmacol       Date:  2007-05-16       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.